As a medication vital for improving patient outcomes, Humira's high cost presents employers with the challenge of balancing financial considerations with the opportunities offered by biosimilars ...

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

Number 3: Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety and efficacy after being switched to another ranibizumab ...

Overall, the study’s findings support the use of Amjevita and Imraldi as equally effective alternatives to Humira in the real ...

Opens in a new tab or window Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the ...

The U.S. biosimilars market also saw five new product launches in 2024. Two of these newly launched products — Simlandi®, referencing Humira® (adalimumab), and Hercessi™, referencing ...

Since we rolled out Connect 360 Autoimmune in 2023, we’ve transitioned over 90% of our members to the biosimilar, Yusimry, and lowered Humira spend for clients by 90%.” In addition to the ...

and recommend less expensive biosimilar versions of the medicine instead. August 26, 2024 Cigna to remove AbbVie's Humira from some drug reimbursement lists next year Cigna said on Monday it will ...